Print Page  |  Close Window

2017 Press Releases

Keyword Search
 

2017 | 2016 | 2015
DateTitle 
11/09/17Avinger Announces Third Quarter 2017 Results
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the third quarter ended September 30, 2017. Third Quarter and Recent Highlights Revenue of $2.1 million, a 16% sequential decrease from the second quarter of 2017 September 30, 2017 cash balance of $10.2 million, including net proceeds of $3.2M raised through the ... 
Printer Friendly Version
11/06/17Avinger Enters into Common Stock Purchase Agreement for up to $15.0 Million with Lincoln Park Capital
REDWOOD CITY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a $15 million common stock purchase agreement (“Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.  The Company is filing a registration statement with the SEC relating to the transaction, and upon its effectiveness,... 
Printer Friendly Version
10/31/17Avinger Receives 510(k) Clearance for Design Modifications to Enhance Performance of Pantheris Image-Guided Atherectomy Device
Updates to First-Ever Image-Guided Atherectomy Device Designed to Improve Efficiency, Reliability, and Ease of Use for Physicians REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for modifications to the company’s Pantheris® Lumivascular atherectomy system. The 510(k... 
Printer Friendly Version
10/31/17Avinger to Announce Third Quarter 2017 Results on November 9, 2017
REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2017 after the close of trading on Thursday, November 9, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 ... 
Printer Friendly Version
10/19/17Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris Image-Guided Atherectomy System for Treatment of In-Stent Restenosis
INSIGHT Clinical Trial to Evaluate Safety and Effectiveness of Pantheris Image-Guided Atherectomy to Treat In-Stent Restenosis in Lower Extremity Arteries REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of INSIGHT, a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris® Lumivascular Atherectom... 
Printer Friendly Version
09/26/17Avinger Receives CE Marking Approval for In-Stent Restenosis Treatment Indication With Pantheris Image-Guided Atherectomy
Pantheris Image-Guided Atherectomy Device Designed to Empower Physicians to Precisely Treat Peripheral Artery Disease REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the Pantheris® Lumivascular atherectomy system. In-stent restenosis occurs when a previously blocked artery tr... 
Printer Friendly Version
08/08/17Avinger Announces Second Quarter 2017 Results
REDWOOD CITY, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2017. Second Quarter and Recent Highlights Executed strategic reorganization in April, reducing sales headcount by approximately 50% and resulting in a significant reduction in cash usage Revenue of $2.5 million, a 30% sequential decrease from... 
Printer Friendly Version
08/03/17Avinger Announces Participation in Canaccord Genuity 37th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Canaccord Genuity 37th Annual Growth Conference in Boston. Avinger management is scheduled to present on Thursday, August 10, 2017 at 10:30am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s websi... 
Printer Friendly Version
07/26/17Avinger to Announce Second Quarter 2017 Results on August 8, 2017
REDWOOD CITY, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2017 after the close of trading on Tuesday, August 8, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 fo... 
Printer Friendly Version
05/31/17Avinger Announces Verified Data of 24-Month Outcomes from the Pivotal VISION Study of Lumivascular Technology for Peripheral Artery Disease
Data Presented at New Cardiovascular Horizons (NCVH) REDWOOD CITY, Calif., and NEW ORLEANS, May 31, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular™ technology. The VISION study was designed to evaluate the safety and effectiveness of Avinger’s Pantheris® system to perform directional atherectomy ... 
Printer Friendly Version
05/25/17Avinger Announces Presentations Showcasing Lumivascular Technology at New Cardiovascular Horizons 18th Annual Conference
REDWOOD CITY, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions highlighting the company’s Lumivascular™ technology at the upcoming New Cardiovascular Horizons conference taking place next week in New Orleans from Tuesday, May 30, through Friday, June 2, 2017. Avinger Lumivascular technology highlights include the following presentations by Patrick Muc... 
Printer Friendly Version
05/04/17Avinger Announces First Quarter 2017 Results
REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the first quarter ended March 31, 2017. First Quarter and Recent Highlights Announced an organizational restructuring, which is expected to reduce net cash use to approximately $7 million per quarter by the third quarter of 2017, a reduction of 48% from the average quarterly cas... 
Printer Friendly Version
05/01/17Avinger to Announce First Quarter 2017 Results on May 4, 2017
REDWOOD CITY, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it will release its financial results for the first quarter of 2017 after the close of trading on Thursday, May 4, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 fo... 
Printer Friendly Version
04/24/17Avinger’s Pantheris Named a 2017 Gold Edison Award Winner
New York Award Ceremony Honors First-Ever Image-Guided Atherectomy Device for Treatment of Peripheral Artery Disease REDWOOD CITY, Calif. and NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), was honored at the 2017 Edison Awards™ in the Medical/Dental Surgical Tool category with gold for Pantheris, the first-ever image-guided atherectomy device for the treatment of PAD. Avinger was nomin... 
Printer Friendly Version
04/10/17Avinger Provides Strategic Update
Announces Preliminary First Quarter 2017 Results REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today provided an update on several aspects of its business, including preliminary results for the first quarter of 2017, an organizational realignment, and continued progress on product development and clinical initiatives.  The Company also announced that it h... 
Printer Friendly Version
03/06/17Avinger Announces Fourth Quarter and Full Year 2016 Results
REDWOOD CITY, Calif. , March 06, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a leading developer of innovative treatments for peripheral artery disease ("PAD"), today reported results for the fourth quarter and full year ended December 31, 2016 . Fourth Quarter and Recent Highlights Revenue of $4.7 million , a 64% increase compared to the fourth quarter of 2015 Added 13 Lumivascular™ accounts, expanding the installed base of the Company's Lumivascular pl... 
Printer Friendly Version
02/22/17Avinger to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that the Company will be participating in two upcoming investor conferences. Avinger’s management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 11:20am ET. Avinger’s management is also scheduled to present at the Oppenheimer 2... 
Printer Friendly Version
02/21/17Avinger to Announce Fourth Quarter and Full Year 2016 Results on March 6, 2017
REDWOOD CITY, Calif. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease ("PAD"), today announced that it will release its financial results for the fourth quarter and full year 2016 after the close of trading on Monday, March 6, 2017 . The Company will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET . Individuals interested in listening to the conference call may do so by ... 
Printer Friendly Version
01/25/17Avinger Announces 24-Month Outcomes from the Pivotal VISION Study of Lumivascular Technology for Peripheral Artery Disease
Interim data presented at Leipzig Interventional Course (LINC) REDWOOD CITY, Calif. and LEIPZIG, Germany, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular™ technology. The VISION study was designed to evaluate the safety and effectiveness of Avinger’s Pantheris™ system to perform direction... 
Printer Friendly Version
01/19/17Avinger Announces Presentations Showcasing Lumivascular Technology at Leipzig Interventional Course
REDWOOD CITY, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of abstracts and sessions highlighting the company’s Lumivascular™ technology at the upcoming Leipzig Interventional Course (LINC) taking place next week in Leipzig, Germany, from Tuesday, January 24, through Friday, January 27, 2017. Avinger Lumivascular technology highlights include the following s... 
Printer Friendly Version
01/06/17Avinger Announces Preliminary Fourth Quarter 2016 Results
REDWOOD CITY, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that based on preliminary unaudited financial results, it expects total revenue of approximately $4.7 million for the fourth quarter ended December 31, 2016, an increase of 62% from the fourth quarter of 2015 and a decrease of 11% from the third quarter of 2016.  Revenue from disposable devices is expected to... 
Printer Friendly Version